Savara (NASDAQ:SVRA) Trading Up 6% – Should You Buy?

Savara Inc (NASDAQ:SVRA)’s share price traded up 6% on Tuesday . The company traded as high as $3.52 and last traded at $3.51. 1,175,703 shares were traded during trading, a decline of 7% from the average session volume of 1,258,246 shares. The stock had previously closed at $3.31.

Analyst Ratings Changes

Several research analysts have commented on SVRA shares. Evercore ISI reissued an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright decreased their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Savara has an average rating of “Moderate Buy” and an average target price of $10.17.

Savara Trading Up 5.7 %

The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a 50-day simple moving average of $3.63 and a 200-day simple moving average of $4.06.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). Sell-side analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Savara news, Director Joseph S. Mccracken acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, with a total value of $59,000.00. Following the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This represents a 10.48 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after purchasing an additional 148,673 shares during the last quarter. Vestal Point Capital LP lifted its stake in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after buying an additional 1,600,000 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after buying an additional 4,157,385 shares during the period. Nantahala Capital Management LLC increased its position in shares of Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Savara by 54.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock valued at $2,928,000 after acquiring an additional 242,249 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.